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Treatment of the medical condition generally referred to as iron overload through the delivery of
chelators has recently received a major boost. In 2005 Novartis gained FDA approval for the drug
deferasirox, which may be taken orally. Until this time most patients with Fe overload have had to
endure long periods of subcutaneous infusions of the orally ineffective drug desferrioxamine (desferal)
which has led to major problems with patient compliance. An effective Fe chelator must possess a
number of properties for it to be able to complex Fe in vivo and be excreted intact. This Perspective will
provide an overview of the current state of chelators for Fe overload; both those currently approved and
those undergoing preclinical development.
1. Introduction
Iron is an essential and ubiquitous element in all forms of life as it
is involved in a multitude of biological processes, yet in excess it is
highly toxic. This condition, referred to generally as Fe overload, is
not one butmany diseases. Space does not permit a comprehensive
coverage, and some references to comprehensive reviews on the
topic are included.1–3 Briefly, two of the most common and
serious forms of Fe overload result from genetic hemochromatosis
(unregulated absorption of Fe from the diet) and transfusional
Fe overload.3 The latter is a side effect of life-sustaining blood
transfusions for the treatment of anemias such as b-thalassemia
and sickle cell anemia (both conditions associated with abnormal
hemoglobin synthesis). Humans are particularly susceptible (more
so than other mammals) to Fe overload under conditions of high
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Fe uptake, since they have no activemechanism for the excretion of
excess Fe. Under normal physiological conditions, humans avoid
Fe overload by tightly regulated uptake from the diet involving
hormones such as hepcidin.4,5
There are only a few options available for patients suffering
Fe overload including phlebotomy (the periodic withdrawal of
blood, the standard treatment for genetic hemachromatosis) or
daily chelation therapy, through the administration of drugs that
target excess stores of Fe and facilitate is excretion. Other more
sophisticated approaches involving gene therapy, or bone marrow
and stem cell transplantation offer hope in the future for the
prevention of Fe overload but at present these treatments are not
viable alternatives to chelation therapy.6
Thalassemia, a genetic disorder, in its more severe forms
necessitates patients beginning blood transfusions from infancy.
If this is not possible, death within the first 4 years of life is almost
inevitable.3 However, these same life-sustaining blood transfusions
result in very rapid Fe loading. In the absence of effective chelation
therapy to offset associated Fe loading, thalassemia patients die
from irreversible damage to the heart and/or liver before 20 years
of age. The origin of the toxicity of excess Fe is linked with
oxidative stress resulting from so calledFenton chemistrywhereFe
catalyses the breakdownof hydrogenperoxide to hydroxyl radicals.
A simplified version of this reaction, whose mechanism is in no
way conclusively established,7 is shown in eqn (1)
Fe2+ + H2O2 → Fe3+ + •OH + OH− (1)
The generation of highly reactive hydroxyl radicals within the
cell may lead to a number of consequences such as DNA damage8
and dysregulation of cellular function.9
2. Chelation therapy
There are four major issues governing the administration of an
Fe chelator: (i) efficacy; (ii) toxicity; (iii) cost and (iv) method of
delivery andassociatedpatient compliancewith its administration.
Obviously a chelator must show a genuine activity to lower Fe
levels. To do this the chelator must gain access to tissues where
Fe loading has occurred, be able to bind Fe competitively and to
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be excreted as an intact Fe complex. The pM scale was introduced
by Raymond and co-workers to provide a way of comparing
directly the metal binding affinities of different ligands at phys-
iological pH 7.4 and under typical biological concentrations of
metal ions and ligands.10 The pM value is calculated from the
concentrationof uncomplexedmetal (M, in this caseFe) remaining
when a solution containing 1 lM metal ion and 10 lM ligand are
at equilibrium at physiological pH 7.4 (pM = −log10[M]).
Fe loading is quantified in humans in various ways including
serum ferritin concentrations (the principal Fe storage protein),
percentage loading of the Fe transport protein transferrin (nor-
mally 20–30% but ∼100% for Fe overload sufferers) and liver
biopsy. More recently, less invasive MRI methods (the T2*
technique)11 and SQUID magnetic susceptibility protocols12 have
emerged as a way of determining Fe loading in the hearts and
livers of patients. These organs are where Fe accumulation results
in the most serious medical conditions. Quantifying cardiac Fe
loading through T2* MRI appears to be a more reliable method
for non-invasive monitoring of the amounts of Fe in the body.
Changes in myocardial Fe loading are relatively slow and serve as
a good indicator for total body Fe levels,13 while liver Fe stores are
much more kinetically labile and can drop rapidly in response to
chelation therapy thus giving a much underestimated indication
of total Fe body loading (in particular the heart).
Apart from being non-toxic and active (Phase I and II trials),
a new chelator must be able to demonstrate ‘non-inferiority’ to
any currently approved treatment (Phase III trial) in order to gain
regulatory approval and to date there are but two that have gained
regulatory approval worldwide (desferrioxamine and deferasirox)
and one other (deferiprone) has gained limited use in some parts
of the world.
The method of administration and the cost of a drug are also
very important factors. The incidence of Fe overload from b-
thalassemia is at its highest in the developing world. It has been
branded an ‘orphan disease’ in theWest due to its rare occurrence.3
Put another way, an estimated 80–95% of the world’s thalassemia
patients live in the economically developing areas of the world
including South-East Asia, India and the Middle East.3,14 There
has been a continuing controversy surrounding the approval (and
non-approval) of certain compounds for the treatment for Fe
overload, and economic issues relating to the availability and
affordability of drugs in the parts of the world that most need
themhave fuelled the debate. References to some articles providing
an overview of the ongoing discussion are given.6,15 Without
entering into this debate, this review shall focus on the known Fe
coordination chemistry of ligands that have shown, or may show,
the ability to mobilize Fe from patients suffering Fe overload. The
aim is to provide a molecular view of the structure and properties
of the chelators and their putative Fe complexes formed in vivo.
3. Fe chelators currently in clinical use
(i) Desferrioxamine
The hexadentate chelator desferrioxamine B (DFO) was identified
more than 40 years ago as an effective biologically active Fe
chelator.16–19 It was released in the 1960s as the first clinically
approved chelator for the treatment of Fe overload. The com-
poundwasoriginally isolated from the fungusStreptomyces pilosus
where its natural function is indeed as a siderophore (to sequester
Fe). Its total synthesis was published20 some time later. There are
other close relatives of DFO that also show similar Fe chelating
properties (Fig. 1).
Fig. 1 The desferrioxamine Fe chelators.
DFO forms an FeIII complex of exceptionally high stability
(pM 26.6).21 Crystal structures of this complex have appeared
recently22,23 revealing a distorted octahedral FeIIIO6 coordination
sphere provided by the three bidentate hydroxamate moieties
(Fig. 2). The crystal structures of the ferric complexes of analogues
such as desferrioxamine D24 and desferrioxamine E25,26 have also
been reported. In all cases the ligand binds as a hexadentate O6
donor where all three hydroxamate groups are deprotonated.
Fig. 2 Crystal structure of ferrioxamineB22 (H-atoms omitted, Fe - green;
O - red; N - blue, C - grey). Coordinates obtained from the Cambridge
Structural Database,27 image created with ORTEP328 and rendered with
PovRay.29
Cyclic voltammetry of [FeIII(DFO)]+ revealed a reversible FeIII/II
couple at −475 mV vs NHE at pH 7.5,30 but reversibility is lost at
lower pH indicative of protonation of the FeII complex. The low
redox potential indicates thatDFO exclusively binds to FeIII in vivo
and that the ferrous oxidation state is essentially inaccessible to
biological reductants.
DFO was patented and developed by Ciba-Geigy in the early
1960s and gainedFDAapproval in 1968 as a drug for the treatment
of Fe overload. Since then,DFOhas prolonged the lives of patients
afflicted with Fe overload who previously would not have survived
past their teen years and has served as the gold standard in Fe
chelation therapy. Patent protection of DFO expired only recently
and generic versions of the drug have been available since 2003.
However, DFO has a number of drawbacks. It cannot be
given orally but instead it can only be delivered by subcutaneous
This journal is © The Royal Society of Chemistry 2007 Dalton Trans., 2007, 3214–3220 | 3215
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infusion. Also, its short plasma life (∼20 min) means that
infusionmust be administered over prolonged and regular periods
(16 hours per day, 5–7 days per week). This has resulted in a
large proportion of patients (∼33%) failing to comply with this
regimen.3 The drug is also very expensive. This is problematic as
the incidence of b-thalassemia it at its highest in economically
developing regions of the world.
Various polymer-bound analogues of DFO have been reported
that maintain the high Fe binding ability of the ligand while
improving the method of delivery. A starch-conjugated DFO
derivative has been reported31 that exhibits a much increased
plasma life (20–30 h) compared with DFO alone (∼20 min). This
offers the possibility of a single daily infusion of this conjugate
instead of the 12–16 h parenteral delivery of DFO. A different
approach, inspired by DFO, has been to produce a hydroxamic
acid polymeric hydrogel32 that may be taken orally and is unable to
be absorbed from the stomach where it sequesters Fe before its hy-
peraccumulation in conditions such as genetic hemochromatosis.
(ii) The 3,4-dihydroxypyridinone (deferiprone) analogues
The problems associated with patient non-compliance and costs
associated with DFO therapy have provided the driving force for
orally active Fe chelators. The first family of compounds to emerge
as potentially orally active drugs for Fe overload chelation therapy
were the 3,4-hydroxypyridinone analogues (Fig. 3) and the first
reports of the Fe coordination chemistry and biological activity of
the lead compound deferiprone (L1) and its analogues appeared
about 20 years ago.33,34
Fig. 3 The 3,4-dihydroxypyridinone Fe chelators.
All ligands from this family form tris-bidentate-coordinated
FeIIIO6 complexes. The hydroxyl group in the 3-position depro-
tonates upon coordination rendering the ensuing FeIII complex
charge neutral. A number of tris-chelated FeIII complexes from this
family havebeen structurally characterised (as shown inFig. 4).34–38
The Fe coordination chemistry and Fe chelation efficacy of
the deferiprone analogues is now very well understood.39 The
ligands are monoprotic acids (pKa 9–10) and their octanol–water
partition coefficients show that they are generally quite hydrophilic
(−1 < logP < 1). The complex formation constants for the 1 :
3 FeIII deferiprone complexes are high (pM 20.0) and the tris-
coordinated ferric complex of deferiprone is dominant above
pH5.39,40 Deferipronewhen present atmillimolar concentrations is
even able to compete with serum transport protein transferrin for
FeIII.39 At more clinically relevant (micromolar) concentrations,
the 3,4-hydroxypyridinones are not competitive with transferrin
for ferric ions. On the other hand, deferiprone has been found to
be capable of releasingFe from the storage protein ferritin,whereas
Fig. 4 Crystal structure of the ferric complex of deferiprone35 (H-atoms
omitted, Fe - green; O - red; N - blue, C - grey). Coordinates obtained from
the Cambridge Structural Database,27 image created with ORTEP328 and
rendered with PovRay.29
the larger DFO cannot. This may be attributed to the smaller size
of deferiprone and its ability to better penetrate the outer shell of
the protein in order to access the ferric oxide/phosphate core of
ferritin. A comparative study of the rate at which deferiprone and
DFO are able to complex weakly bound Fewithin polymeric ferric
citrate has been reported.41 Interestingly, although DFO forms a
more stable ferric complex, deferiprone is capable of complexing
FeIII at a rate almost 10 times greater under typical physiological
concentrations and pH.
Cyclic voltammetry of the ferric complexes of deferiprone,
CP502 and CP509 (Fig. 3) revealed reversible FeIII/II redox couples
at low potential (from −535 to −620 mV vs NHE);42 too low to
be reduced by biological reductants. However, the voltammetry
was dependent on the concentrations of complex and ligand.
At sub-millimolar concentrations, the apparent redox potentials
become pH dependent and undergo large anodic shifts as the pH
is successively lowered below pH 9. Partial dissociation of the
ferrous complexes is attributed to these observations.
The clinical development of deferiprone and its analogues has
been plagued by controversy.15,43 After promising pre-clinical stud-
ies which showed oral activity of deferiprone in animal models,44–46
mixed reports concerning the toxicity and Fe chelating efficacy of
deferiprone in animals47 and then in humans48–51 appeared soon
afterwards. Development of deferiprone was then stopped by its
licensee Ciba-Geigy52 and heated debate followed53–55 concerning
the purported toxicity of the compound weighed against its
possible benefits in being orally active and more acceptable
to patients with Fe overload. Later in the 1990s (when under
development by the Canadian pharmaceutical company Apotex)
controversy again surrounded deferiprone while it was undergoing
further human trials.56
In the absence of a successful Phase III trial (non-inferiority to
DFO) deferiprone never gained FDA approval in the USA as a
drug for the treatment of Fe overload.15 However, deferiprone,
through its oral activity, was the first compound to address
the problem of patient non-compliance with DFO therapy. In
1999 deferiprone finally gained limited approval as an orally
administered Fe chelator in Europe (as well in some other parts
3216 | Dalton Trans., 2007, 3214–3220 This journal is © The Royal Society of Chemistry 2007
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of the world) in cases where DFO therapy cannot be given. It is
currently available in about 50 countries. Recently deferiprone has
found favour in co-administration with DFO57 and in particular
it appears to be effective at reducing severe cardiac Fe loading;58
the most common cause of fatality of patients with Fe overload.
Deferiprone still has many supporters and new clinical studies
continue to appear in parts of the world where the drug is not yet
approved.59 Also a second generation analogue (L1NAll, Fig. 3)
has been promoted as a significant improvement to deferiprone.3
The allyl substituent raises the lipophilicity of the compound and
it demonstrates better Femobilisation activity than deferiprone. It
is metabolised more slowly and apparently is more palatable than
the bitter tasting deferiprone.3
(iii) Deferasirox and its analogues
The bis-hydroxyphenyl-triazole analogues (Fig. 5) are relative
newcomers in the area of clinically useful Fe chelators and there are
few papers60,61 published to date on the Fe coordination chemistry
of this compound or its analogues. Much of what is in the public
domain appeared in a comprehensive paper by Hegetschweiler
and co-workers.61
Fig. 5 The bis-hydroxyphenyl-triazole Fe chelators.
All of the above ligands from this family act as ONO tri-
dentate chelates, with deprotonation of both phenolic groups
accompanying coordination. The Fe complexes have been iso-
lated and characterised spectroscopically, electrochemically and
their formation constants have been determined.61 Potentiometric
titrations of the ligands reveal that the pKa values of the two
phenol groups (in 100% water) lie within the range 8.7 to 11. The
pKa of the carboxylic acid group in deferasirox (H3Lx) is 3.7 so the
ligand is a monoanion at physiological pH 7.4. The FeIII complex
formation constants were determined (logb1 = 22.0, logb2 =
36.9) and speciation data indicate that at pH 7.4, the trianionic
[Fe(Lx)2]3− complex is formed exclusively. Electrochemistry of the
1 : 1 FeIII : L complexes at pH 2.9 revealed that reduction to the
divalent oxidation state is irreversible and accompanied by rapid
dissociation. At pH 12.7, where the bis-ligated complex [Fe(Lx)2]3−
is dominant, a quasi-reversible FeIII/II couple at very low potential
(−580 mV vs NHE) was seen at a Hg working electrode.61 The
reversibility of this redox couple is diminished at lower pH values,
again attributable to partial dissociation of the ferrous complex.
A different group reported a similar redox potential (−600 mV vs
NHE at pH 7.2).42 In either case it can be concluded that the 1 : 2
Fe : L complexes from this family are effectively redox inactive
under physiological conditions. The bis-ligated high spin FeIII
complex [Fe(Lz)2]− has been characterised crystallographically
(Fig. 6).61
Fig. 6 Crystal structure61 of the ferric complex of the deferasirox
analogue Lz (H-atoms omitted, Fe - yellow; O - red; N - blue, C - grey).
Coordinates obtained from the Cambridge Structural Database,27 image
created with ORTEP328 and rendered with PovRay.29
Deferasirox (trade name Exjade, developed by Novartis) was
granted FDA orphan drug status (for fewer than 200 000 potential
recipients) and fast-track status (expeditious review of new drugs
for life threatening conditions). In 2005 it was approved by the
FDA as the first and only drug for use as an orally administered
Fe chelator in the USA. It is also available worldwide. Its arrival
has been heralded as a great breakthrough in the treatment of
Fe overload disorders,62,63 although recent concerns about its use
have been raised in some quarters.64 Unlike deferiprone which has
been given orally in relatively high doses or DFO which must
be delivered subcutaneously and continuously over long periods,
deferasirox may be administered orally in single daily dose due to
its long plasma life (∼12 h).
4. New Fe chelators under investigation
(i) The desferrithiocin analogues
The desferrithiocin analogues (Fig. 7) have been known to show
a wide spectrum of biological activity for more than 40 years. The
first reports with these compounds can be traced to papers from
India in the 1960s65 and 1970s.66 The Fe complex of the parent
compound desferrithiocin was first isolated from Streptomyces
antibioticus in 198067 and the chelator was patented68 in 1987 and
investigated by Ciba-Geigy as a drug for the treatment of malaria.
Fig. 7 The desferrithiocin analogues.
This journal is © The Royal Society of Chemistry 2007 Dalton Trans., 2007, 3214–3220 | 3217
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Desferrithiocin is a diprotic acid with the protonation constants
of the phenolic (pKa 9.9) and carboxylic acid (pKa 3.3) reported.69
It is a potentially tridentateONO chelator and the FeIII (and other
divalentmetal ion) complex formation constants of desferrithiocin
and its demethylated analogue (desmethyldesferrithiocin) have
been reported (logb2 29–30, pM 20.5).69,70 Despite their relevance
to biological activity, publications on the Fe coordination chem-
istry of the desferrithiocin analogues have been conspicuously rare.
The Raymond group reported a comprehensive paper on the Fe
complex of desmethyldesferrithiocin (or nordesferriferrithiocin).70
These chelators, being chiral compounds, lead to a number of pos-
sible diastereomers upon complexation with 6-coordinate metal
ions.71 This seemingly has complicated isolation of Fe complexes
in isomerically pure forms for crystallographic studies. Indeed
very few crystallographically characterised complexes of the des-
ferrithiocin analogues have been published.70–73 Perhaps the most
relevant ones are the AlIII complexes of desferrithiocin (Fig. 8) and
its demethylated analogue.70 In any case, the meridional tridentate
ONO coordination mode of the dianion is clearly established in
all known examples. The FeIII complexes exhibit quasi-reversible
FeIII/II redox couples in water70 in the region −160 to −100 mV vs
NHE, making them accessible to biological reductants.
Fig. 8 Crystal structure of theAlIII complex of desferrithiocin70 (H-atoms
omitted, Al - light grey; O - red; N - blue, S- yellow, C - dark grey).
Coordinates obtained from the Cambridge Structural Database,27 image
created with ORTEP328 and rendered with PovRay.29
Although desferrithiocin demonstrated high Fe chelating ac-
tivity and was orally active, it also exhibited unacceptably high
toxicity. In particular it was found that the FeIII complex of
this ligand was harmful.74,75 Modifications to the basic structure
of the chelator have proven effective in lowering toxicity whilst
retaining activity. A significant improvement in this regard was
replacement of the pyridyl ring with a phenyl ring (the so called
desazadesmethyldesferrithiocin analogues). One of these second
generation analogues, deferitrin (Fig. 7), is now undergoing Phase
II human trials as an orally active Fe chelator.76
(ii) 2-Pyridinecarbaldehyde isonicotinoyl hydrazone (HPCIH)
analogues
Our own interest has been in a class of tridentate ligands derived
from the parent compound 2-pyridinecarbaldehyde isonicotinoyl
hydrazone (HPCIH, Fig. 9). All chelators are monoprotic acids
with the hydrazone NH group being the site of deprotonation
(pKa ∼10) and consequently they are charge neutral at physio-
logical pH 7.4. The ligands are tridentate NNO chelators which
coordinate as their monoanion.
Fig. 9 The HPCIH and H2IPH analogues.
Unlike most other Fe chelators that have been investigated
for potential use in chelation therapy, the HPCIH analogues
exclusively target FeII and not FeIII. This can be attributed to the
influence of the 2-pyridyl moiety in stabilising the lower oxidation
state in comparisonwith phenolate or hydroxamate residues found
in FeIII chelators such as DFO, deferiprone and deferasirox.
The FeIII/II redox potentials of the Fe complexes HPCIH
analogues (> +500 mV vs NHE) are outside the range of
physiological oxidants. The FeII complex formation constants
with the HPCIH analogues are much lower (pM ∼7)77,78 than
found in ferric complexes of DFO, deferiprone and deferasirox.
However it is relevant that electrochemical studies coupled with
known FeIII complex formation constants of DFO,30 deferiprone,
desferrithiocin70 and deferasirox61 indicate that they have an even
lower affinity for FeII. The crystal structure of one of the low
spin FeII complexes of theHPCIH analogues (the 2-bromobenzoic
hydrazone) is shown in Fig. 10.
Fig. 10 Crystal structure of the FeII complex of 2-pyridinecarbaldehyde
2′-bromobenzoyl hydrazone77 (H-atoms omitted, Fe - yellow; O - red;
N - blue, Br- tan, C -grey). Coordinates obtained from the Cambridge
Structural Database,27 image created with ORTEP328 and rendered with
PovRay.29
The HPCIH analogues are very effective at mobilising Fe from
Fe-loaded cells and also at preventing further cellular Fe uptake
from diferric transferrin.77,79 They also show low toxicity. Most
importantly the lead compound from this group (HPCTH, Fig. 9)
has been shown to be orally active in a mouse model.80
3218 | Dalton Trans., 2007, 3214–3220 This journal is © The Royal Society of Chemistry 2007
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The fact that the Fe complex formation constants of theHPCIH
analogues are modest indicates that a highly stable Fe complex
(ferric or ferrous) is not necessary for high Fe chelation efficacy.
The so-called labile iron pool or non-transferrin bound iron
(NTBI) is a poorly characterised source of intracellular Fe that
is believed to be associated with low molecular weight ligands
such as citrate and is hence available to chelators. Indeed it is
Fe from this NTBI pool that is believed to be the target of
current Fe chelators used in the clinic.81 The levels of NTBI
may become elevated in conditions of Fe overload, when serum
transferrin becomes saturated (90–100%) with Fe. Under normal
physiological conditions transferrin is only 20–30% saturated with
Fe. In either case NTBI is believed to be ‘in transit’ and thus
part of a dynamic process of replenishment through cellular Fe
uptake or consumption in protein synthesis.81 The inability of
the HPCIH analogues to directly compete with transferrin for Fe
while (indirectly) being able to prevent cellular Fe uptake from
transferrin points to NTBI as the most likely target.
A number of the HPCIH analogues are very effective in
mobilising Fe from cells77,79 yet we have identified functional
groups that should be avoided in their design. Most particularly
hydrazones with hydrophilic substituents on the non-coordinating
aromatic ring such as –OHand –NH2 that impart undesirably high
hydrophilicity systematically show poor biological activity. The
most active chelators exhibit octanol–water partition coefficients
in the range 2 < logP < 3.77 All other physical data (structural,
spectroscopic, potentiometric) fail to discriminate between the
most and least biologically active Fe chelators.
In the course of our studies of the Fe coordination chem-
istry of the HPCIH analogues, we identified a most unusual
reaction.82 Complexation of HPCIH with FeIII in aerated neutral
aqueous solution leads to the rapid and complete conversion
of [FeIII(PCIH)2]+ (not isolated) to the bis-hydrazine complex
[FeIII(HIPH)(IPH)] (Fig. 11). Like their hydrazone parents, the
hydrazine H2IPH (Fig. 9) and its analogues bind as tridentate
NNO chelators but in this case the central N-donor is one
site of deprotonation. The remaining NH group may also be
deprotonated upon coordination depending on pH. The crystal
Fig. 11 Crystal structure of the FeIII complex of H2IPH82 (H-atoms
omitted, Fe - yellow; O - red; N - blue, C - grey). Coordinates obtained
from the Cambridge Structural Database,27 image created with ORTEP328
and rendered with PovRay.29
structure shown in Fig. 11 finds one ligand doubly deprotonated
while the other is singly deprotonated. We have identified both
1 : 1 and 1 : 2 Fe : ligand complexes of these chelators.83 Most
importantly, the H2IPH analogues have also been found to exhibit
excellent Fe mobilisation properties,83 yet in this case they favour
FeIII over FeII.
The mechanism by which this most unusual hydrazone to
hydrazine conversion occurs (a conversion without precedent in
the organic chemistry literature) is still a subject of ongoing work
but the role of Fe is firmly established as the parent hydrazone
(HPCIH) cannot be converted to its corresponding hydrazine
(H2IPH) in the absence of Fe. Partial conversion of the isomeric 2-
pyridine carbaldehyde picolinoyl hydrazone to its corresponding
hydrazine (H2PPH) was also found to be catalysed by Fe but in
this case a most unusual mixed ligand di-iron triple helicate was
found.84
5. Future prospects
Chelation therapy has proven to be an effective treatment for
Fe overload. b-Thalassemia patients now in their 50s who have
undergoneDFOchelation therapy since childhood are living proof
of the value of this drug. Those afflicted with this disease prior to
the emergence of DFO, or who have been unable to cope with the
demands or cost of DFO therapy, have typically died in their teens.
Compliance with the invasive parenteral administration of DFO
remains a major issue and it has been suggested that at least 33%
of patients (many of them children) do not comply with its invasive
procedure satisfactorily. The very recent emergence of deferasirox
as an approved orally active drug is a major breakthrough in
the treatment of Fe overload and this compound currently is
the benchmark by which all new orally active chelators will be
measured in clinical trials. Deferasirox has still only been used
for a short time and some patients compliant with DFO therapy
have reportedly chosen to remain with this drug until more data
become available on deferasirox.62
Although structure–activity relationships may be used to tune
the biological activity of existing compounds it is still a major
challenge to develop an effective Fe chelator that also is non-toxic.
It is now apparent that some of the features that were first thought
to be critical in the design of an effective Fe chelator such as
charge neutrality andhighFe complex formation constants are not
prerequisites. There is now a broad spectrum of Fe chelators that
have appeared;many of which are charged in both their complexed
and uncomplexed state and many of which are unable to compete
with targets such as diferric-transferrin for Fe. The complexity
of Fe speciation within cells provides different targets (ferric or
ferrous Fe) for chelators of various types and it is clear that there
are many types of chelators, as yet undiscovered, that may prove
effective in the treatment of Fe overload.
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